ADMA Reports Q1 Revenue of $114.49M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Reports Q1 revenue $114.49M, consensus $139.97M. "During the first quarter, the market for U.S. plasma derived therapies and immunoglobulin experienced increased competitive dynamics which, along with variability in distributor ordering patterns, created near-term topline pressures, particularly impacting BIVIGAM," said Adam Grossman, President and Chief Executive Officer of ADMA. "Importantly, these dynamics were limited to distribution and inventory behavior and we believe do not reflect any deterioration in underlying ASCENIV demand, where fundamentals remained strong and continue to improve - with record utilization growth throughout the quarter, as illustrated by ASCENIV's 28% year-over-year revenue growth. We continue to see strength across key ASCENIV demand metrics, including record new patient starts, growing prescriber breadth, product pull-through and patient adherence, and we are encouraged that the second quarter run rate based on April demand is in-line with the level of first quarter direct sales."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiation: ADMA Biologics is facing a class action lawsuit for alleged violations of the Securities Exchange Act between August 9, 2024, and March 25, 2026, with investors having until August 10, 2026, to apply as lead plaintiffs, indicating significant legal risks that could undermine market confidence in the company.
- Allegations of Misrepresentation: The lawsuit claims that ADMA Biologics failed to disclose related party transactions and engaged in channel stuffing to inflate revenue, which, if proven true, could severely impact the company's financial health and erode investor trust.
- Stock Price Volatility: Following a report from Culper Research alleging that ADMA's growth figures were fabricated, the stock price plummeted over 16% on March 24, 2026, and further declined by more than 13% after the company's response, highlighting market concerns regarding the company's transparency.
- Law Firm Credentials: Robbins Geller Rudman & Dowd LLP, a leading securities litigation firm, has recovered $8.4 billion for investors over the past five years, showcasing its strength in securities fraud cases, which may significantly influence the legal outcomes for ADMA Biologics.
See More
Reminder of ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the filed class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing to inflate revenue, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in leadership roles, avoiding firms that merely act as intermediaries to ensure effective legal support in class actions.
See More
Notice to ADMA Biologics Shareholders Regarding Class Action Lawsuit
- Lawsuit Background: The Gross Law Firm has issued a notice encouraging shareholders who purchased ADMA Biologics stock between August 9, 2024, and March 25, 2026, to contact them regarding potential lead plaintiff appointment, indicating the company faces significant legal liabilities.
- Allegations: The complaint alleges that ADMA Biologics engaged in undisclosed related party transactions, used channel stuffing to create an illusion of revenue, and lacked adequate internal controls, resulting in materially false and misleading statements about the company's business and prospects.
- Shareholder Action Recommendation: Shareholders are advised to register for the class action by August 10, 2026, and upon registration, they will be enrolled in a portfolio monitoring system to receive status updates throughout the case lifecycle, ensuring they remain informed about developments.
- Law Firm Background: The Gross Law Firm is a nationally recognized class action law firm committed to protecting the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the need for companies to adhere to responsible business practices.
See More
Faruqi & Faruqi Encourages ADMA Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against ADMA Biologics, particularly for investors who purchased or acquired securities between August 9, 2024, and March 25, 2026, highlighting concerns over the company's future legal risks.
- Investor Rights Reminder: The firm reminds investors that August 10, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, a critical date that could affect the validity of their claims.
- Direct Contact Channels: Investors can reach out directly to Faruq & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for detailed information regarding their legal rights, demonstrating the firm's commitment to client service.
- Background on Securities Class Action: This investigation is related to an existing federal securities class action filed against ADMA Biologics, indicating potential legal liabilities for the company, which investors need to monitor for possible financial impacts.
See More
ADMA Biologics Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for securities fraud, primarily due to allegations that its reported 20% growth for 2025 was driven by a channel stuffing scheme, resulting in significant stock price drops and substantial investor losses.
- Stock Price Plunge: On March 24, 2026, ADMA's stock fell from $13.59 to $11.33, a 16.6% drop, followed by a further 15% decline the next day, reflecting severe market concerns regarding the company's financial health.
- Legal Action: Investors are encouraged to apply to be lead plaintiffs by August 10, 2026, indicating a crisis of trust in the company's executives and financial reporting, which could lead to broader legal ramifications.
- Market Reaction: A report from Culper Research revealed that ADMA's revenue growth was not genuine, suggesting that without the alleged channel stuffing, the company would have faced a 3% revenue decline in 2025, exacerbating the market's trust crisis in ADMA.
See More
Investors Alert: Class Action Lawsuits Against ADMA, ERAS, NNOX
- ADMA Class Action: The class action lawsuit against ADMA Biologics, Inc. alleges that the company made materially false or misleading statements between August 9, 2024, and March 25, 2026, leading to investor losses, with a deadline of August 10, 2026, for investors to apply as lead plaintiffs to protect their rights.
- ERAS Legal Action: Similarly, the class action lawsuit against Erasca, Inc. claims that the company failed to disclose material facts from January 14, 2025, to April 26, 2026, and investors who purchased shares during this period and suffered losses are encouraged to contact legal counsel before the August 10, 2026 deadline.
- NNOX Lawsuit Details: The class action against Nano-X Imaging Ltd. alleges that the company made false statements regarding operational efficiency and cash burn from March 31, 2025, to April 17, 2026, with affected investors needing to apply as lead plaintiffs by August 11, 2026.
- Law Firm Background: Holzer & Holzer, LLC, a top-rated securities litigation firm, has been dedicated to representing shareholders since 2000, recovering hundreds of millions for investors affected by fraud, emphasizing its commitment to vigorous legal representation.
See More
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiation: ADMA Biologics is facing a class action lawsuit for alleged violations of the Securities Exchange Act between August 9, 2024, and March 25, 2026, with investors having until August 10, 2026, to apply as lead plaintiffs, indicating significant legal risks that could undermine market confidence in the company.
- Allegations of Misrepresentation: The lawsuit claims that ADMA Biologics failed to disclose related party transactions and engaged in channel stuffing to inflate revenue, which, if proven true, could severely impact the company's financial health and erode investor trust.
- Stock Price Volatility: Following a report from Culper Research alleging that ADMA's growth figures were fabricated, the stock price plummeted over 16% on March 24, 2026, and further declined by more than 13% after the company's response, highlighting market concerns regarding the company's transparency.
- Law Firm Credentials: Robbins Geller Rudman & Dowd LLP, a leading securities litigation firm, has recovered $8.4 billion for investors over the past five years, showcasing its strength in securities fraud cases, which may significantly influence the legal outcomes for ADMA Biologics.
See More
Reminder of ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the filed class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing to inflate revenue, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in leadership roles, avoiding firms that merely act as intermediaries to ensure effective legal support in class actions.
See More
Notice to ADMA Biologics Shareholders Regarding Class Action Lawsuit
- Lawsuit Background: The Gross Law Firm has issued a notice encouraging shareholders who purchased ADMA Biologics stock between August 9, 2024, and March 25, 2026, to contact them regarding potential lead plaintiff appointment, indicating the company faces significant legal liabilities.
- Allegations: The complaint alleges that ADMA Biologics engaged in undisclosed related party transactions, used channel stuffing to create an illusion of revenue, and lacked adequate internal controls, resulting in materially false and misleading statements about the company's business and prospects.
- Shareholder Action Recommendation: Shareholders are advised to register for the class action by August 10, 2026, and upon registration, they will be enrolled in a portfolio monitoring system to receive status updates throughout the case lifecycle, ensuring they remain informed about developments.
- Law Firm Background: The Gross Law Firm is a nationally recognized class action law firm committed to protecting the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the need for companies to adhere to responsible business practices.
See More
Faruqi & Faruqi Encourages ADMA Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against ADMA Biologics, particularly for investors who purchased or acquired securities between August 9, 2024, and March 25, 2026, highlighting concerns over the company's future legal risks.
- Investor Rights Reminder: The firm reminds investors that August 10, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, a critical date that could affect the validity of their claims.
- Direct Contact Channels: Investors can reach out directly to Faruq & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for detailed information regarding their legal rights, demonstrating the firm's commitment to client service.
- Background on Securities Class Action: This investigation is related to an existing federal securities class action filed against ADMA Biologics, indicating potential legal liabilities for the company, which investors need to monitor for possible financial impacts.
See More
ADMA Biologics Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for securities fraud, primarily due to allegations that its reported 20% growth for 2025 was driven by a channel stuffing scheme, resulting in significant stock price drops and substantial investor losses.
- Stock Price Plunge: On March 24, 2026, ADMA's stock fell from $13.59 to $11.33, a 16.6% drop, followed by a further 15% decline the next day, reflecting severe market concerns regarding the company's financial health.
- Legal Action: Investors are encouraged to apply to be lead plaintiffs by August 10, 2026, indicating a crisis of trust in the company's executives and financial reporting, which could lead to broader legal ramifications.
- Market Reaction: A report from Culper Research revealed that ADMA's revenue growth was not genuine, suggesting that without the alleged channel stuffing, the company would have faced a 3% revenue decline in 2025, exacerbating the market's trust crisis in ADMA.
See More
Investors Alert: Class Action Lawsuits Against ADMA, ERAS, NNOX
- ADMA Class Action: The class action lawsuit against ADMA Biologics, Inc. alleges that the company made materially false or misleading statements between August 9, 2024, and March 25, 2026, leading to investor losses, with a deadline of August 10, 2026, for investors to apply as lead plaintiffs to protect their rights.
- ERAS Legal Action: Similarly, the class action lawsuit against Erasca, Inc. claims that the company failed to disclose material facts from January 14, 2025, to April 26, 2026, and investors who purchased shares during this period and suffered losses are encouraged to contact legal counsel before the August 10, 2026 deadline.
- NNOX Lawsuit Details: The class action against Nano-X Imaging Ltd. alleges that the company made false statements regarding operational efficiency and cash burn from March 31, 2025, to April 17, 2026, with affected investors needing to apply as lead plaintiffs by August 11, 2026.
- Law Firm Background: Holzer & Holzer, LLC, a top-rated securities litigation firm, has been dedicated to representing shareholders since 2000, recovering hundreds of millions for investors affected by fraud, emphasizing its commitment to vigorous legal representation.
See More
